Sorrento”s anti-SARS-CoV-2 antibody, STI-1499, completely neutralised the virus infectivity at a very low antibody dose, making it a prime candidate for further testing and development. Initial biochemical and biophysical analyses also indicate STI-1499 is a potentially strong antibody drug candidate, said the antibody-centric biopharmaceutical company headquartered in San Diego, California. “Our STI-1499 antibody shows exceptional therapeutic potential and … Continue reading COVID-19 : Antibodies demonstrated the ability to block the S1 protein”s interaction